Selected article for: "antibody response and clinical vaccine"
Author: Ali, Ahya; Dwyer, Deanna; Wu, Qi; Wang, Qin; Dowling, Catherine A.; Fox, David A.; Khanna, Dinesh; Poland, Gregory A.; Mao-Draayer, Yang
Title: Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
  • Cord-id: 9560enkl
  • Document date: 2021_9_2
    • ID: 9560enkl
    Snippet: Little is known about COVID-19 mRNA vaccine humoral immune responses in patients with central nervous system autoimmune demyelinating diseases, multiple sclerosis (MS) and neuromyelitis optica (NMO), who are on B-cell depleting therapies (BCDT) and other disease modifying therapies (DMTs). We conducted a single center prospective study to identify the clinical and immunological features associated with vaccine-induced antibody response in 53 participants before and after COVID-19 mRNA vaccinatio
    Document: Little is known about COVID-19 mRNA vaccine humoral immune responses in patients with central nervous system autoimmune demyelinating diseases, multiple sclerosis (MS) and neuromyelitis optica (NMO), who are on B-cell depleting therapies (BCDT) and other disease modifying therapies (DMTs). We conducted a single center prospective study to identify the clinical and immunological features associated with vaccine-induced antibody response in 53 participants before and after COVID-19 mRNA vaccination. This is the first report on the anti-spike RBD and anti-nucleocapsid antibody response, along with pre- and post-vaccine absolute lymphocyte counts (ALC) and flow cytometry analysis of CD19 and CD20 lymphocytes in patients with MS and NMO. We tested the hypothesis that patients on BCDT may have impaired COVID-19 vaccine humoral responses. Among patients on BCDT, 36.4% demonstrated a positive antibody response to spike RBD, in comparison to 100% in all other groups such as healthy controls, untreated MS, and patients on non-B cell depleting DMTs (p < 0.0001). Immunological data revealed lower baseline (pre-vaccination) levels of IgM in patients on BCDT (p = 0.003). Low CD19 and CD20 counts and a shorter interval from the last B cell depleting therapy infusion to the first vaccine dose were associated with a negative spike RBD antibody response (non-seroconverter) in patients on BCDT. Age, body mass index (BMI) and total treatment duration did not differ between seroconverters and non-seroconverters.

    Search related documents:
    Co phrase search for related documents
    • absence presence and additional study: 1, 2, 3, 4
    • absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and logistic regression model: 1, 2, 3, 4, 5, 6, 7
    • absence presence and longitudinal study: 1, 2, 3, 4, 5, 6
    • absolute count and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absolute count and logistic regression model: 1, 2, 3, 4, 5, 6, 7
    • absolute count and longitudinal study: 1
    • absolute lymphocyte count alc and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absolute lymphocyte count alc and logistic regression model: 1, 2
    • absolute lymphocyte count and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absolute lymphocyte count and logistic regression model: 1, 2, 3, 4, 5, 6
    • absolute lymphocyte count and longitudinal study: 1
    • additional study and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • additional study and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8
    • local muscle pain and longitudinal study: 1
    • logistic regression and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • logistic regression model and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11